79561-82-3

Basic information

• Product Name: (R)-N-BOC-4-Bromophenylalanine
• Synonyms: RARECHEM BK PT 0047;(R)-N-BOC-4-BROMOPHENYLALANINE;(R)-3-(4-BROMO-PHENYL)-2-TERT-BUTOXYCARBONYLAMINO-PROPIONIC ACID;N-ALPHA-T-BUTOXYCARBONYL-4-BROMO-D-PHENYLALANINE;N-ALPHA-TERT-BUTYLOXYCARBONYL-D-4-BROMOPHENYLALANINE;BOC-(R)-2-AMINO-3-(4'-BROMOPHENYL)PROPANOIC ACID;BOC-4'-BROMO-D-PHE;BOC-4-BROMO-D-PHENYLALANINE
• CAS NO: 79561-82-3
• Molecular Formula: C14H18BrNO4
• Molecular Weight: 344.2
• Product Categories: Amino Acids;Phenylalanine analogs and other aromatic alpha amino acids;Amino Acid Derivatives;a-amino
• Mol File: 79561-82-3.mol
• Article Data: 23

Chemical Properties

• Melting Point: 117.0 to 121.0 °C
• Boiling Point: 475.3 °C at 760 mmHg
• Flash Point: 241.2 °C
• Appearance: off-white crystalline powder
• Density: 1.5311 (rough estimate)
• Vapor Pressure: 7.71E-10mmHg at 25°C
• Refractive Index: 1.6500 (estimate)
• Storage Temp.: Store at RT.
• Solubility: soluble in Methanol
• PKA: 3.83±0.10(Predicted)
• CAS DataBase Reference: (R)-N-BOC-4-Bromophenylalanine(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-N-BOC-4-Bromophenylalanine(79561-82-3)
• EPA Substance Registry System: (R)-N-BOC-4-Bromophenylalanine(79561-82-3)

Safety Data

• Hazard Codes: Xi
• Safety Statements: S24/25:Avoid contact with skin and eyes.
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 79561-82-3(Hazardous Substances Data)

Usage

Chemical Properties

off-white crystalline powder

InChI:InChI=1/C14H18BrNO4/c1-14(2,3)20-13(19)16-11(12(17)18)8-9-4-6-10(15)7-5-9/h4-7,11H,8H2,1-3H3,(H,16,19)(H,17,18)/p-1/t11-/m1/s1

Upstream product

• 1213855-60-7 methyl (R)-3-(4-bromophenyl)-2-((tert-butoxycarbonyl)amino)propanoate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 122839-59-2 (S)-2-amino-3-(4-bromophenyl)propanoic acid hydrochloride 
• 1200-07-3 3-(4-bromophenyl)acrylic acid 
• 24250-84-8 H-p-BrPhe-OH 
• 38712-59-3 3-(4-bromophenyl)-2-carbonylpropionic acid 
• 62561-74-4 (2R)-2-amino-3-(4-bromophenyl)propanoic acid 
• 108540-72-3 4-bromophenylalanine-hydrochloride 
• 14091-15-7 p-bromo-DL-phenylalanine 

Downstream Products

• 99359-32-7 (S)-2-amino-3-(4-bromophenyl)propionic acid methyl ester hydrochloride 
• 128779-47-5 (2R)-3-(biphenyl-4-yl)-2-[(tert-butoxycarbonyl)amino]propanoic acid 
• 1016643-98-3 Boc-Bip(4-Ph)-OH 
• 1562405-29-1 (2S,4R)-benzyl 4-((tert-butoxycarbonyl)amino)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-2-methylpentanoate 
• 1562404-57-2 (2S,4R)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid 
• 119273-61-9 N-tert-butoxycarbonyl-p-phenyl-L-phenylalanine 

Relevant articles and documents

Enantioselective Deaminative Alkylation of Amino Acid Derivatives with Unactivated Olefins

Herein, we report the first Ni-catalyzed enantioselective deaminative alkylation of amino acid and peptide derivatives with unactivated olefins. Key for success was the discovery of a new sterically encumbered bis(oxazoline) ligand backbone, thus offering a de novo technology for accessing enantioenriched sp3-sp3 linkages via sp3 C-N functionalization. Our protocol is distinguished by its broad scope and generality across a wide number of counterparts, even in the context of late-stage functionalization. In addition, an enantioselective deaminative remote hydroalkylation reaction of unactivated internal olefins is within reach, thus providing a useful entry point for forging enantioenriched sp3-sp3 centers at remote sp3 C-H sites.

Preparation method of 2-NH-Boc-3-(3',4'-dimethyl-[1,1'-biphenyl]-4)propionic acid

The invention relates to a preparation method of 2-NH-Boc-3-(3',4'-dimethyl-[1,1'-biphenyl]-4)propionic acid, and mainly solves the technical problem of lack of industrial preparation of the 2-NH-Boc-3-(3',4'-dimethyl-[1,1'-biphenyl]-4)propionic acid at p

NOVEL PROCESS FOR THE PREPARATION OF SACUBITRIL AND ITS INTERMEDIATES

A process for the preparation of sacubitril and its intermediates is disclosed. By practicing the methods disclosed herein, a solid form of sacubitril may be generated. A crystalline form of sacubitril is also disclosed.